Viridian Therapeutics, Inc. Common Stock (VRDN) Stock Price

VRDNStock

$19.03−17.30%52W

Market Cap$2.16B

P/E—

PEG Ratio—

Div yield—

Beta1.12

VRDN Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)15.37%

Price vs S&P 500 (4W)-10.49%

VGM Score66.06

Book Value / Share (Quarterly)$5.85

P/TBV (Annual)2.17x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)242.07%

Cash Flow / Share (Quarterly)$-2.96

Price vs S&P 500 (YTD)-50.78%

Gross Margin (TTM)2.36%

Net Profit Margin (TTM)-544.06%

EPS (TTM)$-3.90

10-Day Avg Trading Volume2.27M

EPS Excl Extra (TTM)$-3.90

Revenue Growth (5Y)132.18%

EPS (Annual)$-4.04

ROI (Annual)-42.49%

Gross Margin (Annual)2.76%

Net Profit Margin (5Y Avg)-35120.44%

Cash / Share (Quarterly)$8.67

Revenue Growth QoQ (YoY)278.67%

ROA (Last FY)-38.09%

Revenue Growth TTM (YoY)23220.33%

EBITD / Share (TTM)$-4.19

ROE (5Y Avg)-43.32%

Operating Margin (TTM)-569.68%

Cash Flow / Share (Annual)$-2.72

P/B Ratio3.26x

P/B Ratio (Quarterly)3.06x

Net Income / Employee (Annual)$-1,359,500

EV / Revenue (TTM)32.99x

Net Interest Coverage (TTM)-324.65x

ROA (TTM)-46.03%

EPS Incl Extra (Annual)$-4.04

Current Ratio (Annual)12.65x

Quick Ratio (Quarterly)16.56x

3-Month Avg Trading Volume1.94M

52-Week Price Return-17.30%

Revenue / Employee (TTM)$282,300

Tangible BV / Share (Quarterly)$5.76

P/S Ratio (Annual)30.43x

Asset Turnover (Annual)0.08x

52-Week High$34.29

Operating Margin (5Y Avg)-38169.46%

EPS Excl Extra (Annual)$-4.04

CapEx CAGR (5Y)65.39%

Tangible BV CAGR (5Y)59.30%

26-Week Price Return25.28%

Quick Ratio (Annual)12.37x

13-Week Price Return5.55%

Total Debt / Equity (Annual)0.12x

Current Ratio (Quarterly)16.95x

Enterprise Value$2.35B

Revenue / Share Growth (5Y)23.16%

Asset Turnover (TTM)0.08x

Book Value / Share Growth (5Y)-24.33%

Revenue / Employee (Annual)$281,100

Inventory Turnover (Annual)12.35x

Pretax Margin (Annual)-483.57%

Cash / Share (Annual)$8.59

3-Month Return Std Dev46.06%

Gross Margin (5Y Avg)13.95%

Net Income / Employee (TTM)$-1,535,600

ROE (Last FY)-47.44%

Net Interest Coverage (Annual)-125.24x

EPS Basic Excl Extra (Annual)$-4.04

Receivables Turnover (TTM)2.02x

Total Debt / Equity (Quarterly)0.54x

EPS Incl Extra (TTM)$-3.90

Receivables Turnover (Annual)5.92x

ROI (TTM)-50.41%

P/S Ratio (TTM)30.31x

Pretax Margin (5Y Avg)-35120.44%

Revenue / Share (Annual)$0.84

Tangible BV / Share (Annual)$9.56

Price vs S&P 500 (52W)-32.83%

Year-to-Date Return-38.85%

5-Day Price Return3.99%

EPS Normalized (Annual)$-4.04

ROA (5Y Avg)-38.35%

Net Profit Margin (Annual)-483.57%

Month-to-Date Return-7.58%

Cash Flow / Share (TTM)$-5.09

EBITD / Share (Annual)$-4.28

Operating Margin (Annual)-512.91%

LT Debt / Equity (Annual)0.12x

ROI (5Y Avg)-41.54%

LT Debt / Equity (Quarterly)0.54x

EPS Basic Excl Extra (TTM)$-3.90

P/TBV (Quarterly)3.11x

P/B Ratio (Annual)4.11x

Inventory Turnover (TTM)12.40x

Pretax Margin (TTM)-544.06%

Book Value / Share (Annual)$7.09

Price vs S&P 500 (13W)2.86%

Beta1.12x

Revenue / Share (TTM)$0.66

ROE (TTM)-61.35%

52-Week Low$13.18

vGradeD

gGradeA

mGradeB

vgmGradeB

VRDN Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 6, 2026	-$1.03	-$1.05	-2.31%(-$0.02)
Q1 2026	May 5, 2026	-$1.08	-$0.90	+16.28%(+$0.18)
Q4 2025	Feb 26, 2026	-$1.00	-$1.08	-7.96%(-$0.08)
Q3 2025	Nov 5, 2025	-$0.94	-$0.34	+63.91%(+$0.60)
Q2 2025	Aug 6, 2025	-$0.98	-$1.00	-1.57%(-$0.02)

VRDN Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.26

4.30

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
VRDNViridian Therapeutics, Inc. Common Stock	D	A	B	30.3x	23220.3%	2.4%	—	$19.03
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Viridian Therapeutics, Inc. Common Stock

Viridian Therapeutics is a clinical-stage biopharmaceutical company developing therapies for thyroid eye disease. Its lead candidate, Veligrotug, is a humanized monoclonal antibody targeting IGF-1R, available in both intravenous and subcutaneous formulations.

VRDN Next Earnings Report

Report dateNov 5, 2026

QuarterQ3 2026

Report timeBMO

EPS estimate-$1.02

Revenue estimate$4.68M

Also reporting on Nov 5, 2026

Scheduled date with consensus estimates — both can change before the company reports.

Earnings calendar for November 2026

VRDN Insider Transactions

SellAug 19, 2026
TOUSIGNANT JENNIFER
Officer
Shares: 14,212Value: $348,194

Open-market buys and sells filed with the SEC over the last 90 days. Grants, gifts and option exercises are excluded.

All insider transactions for August 2026

Companies in Related Industries

ADMAADMA Biologics, Inc.Biological Products
IOSPInnospec Inc.Chemicals
ROGRogers CorporationPlastics & Resins
CLDXCelldex Therapeutics, IncIn Vitro Diagnostics
VCELVericel CorporationBiological Products
BCRXBioCryst Pharmaceuticals IncBiological Products
MTXMinerals Technologies IncIndustrial Chemicals
STDNStandard Nuclear, Inc.Industrial Chemicals

Same SIC sector, outside this company's own industry.

Analyst Sentiment

4.3

Strong Buy

Consensus rating

52-Week Range

Low$13.18

High$34.29